title: Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study.
abstract: BACKGROUND
  Low-dose aspirin is widely used for the prevention of cardiovascular events. The prevalence of gastroduodenal injuries and the risk factor profile including gastroprotective drug therapy needs to be clarified in Japanese patients taking daily aspirin for cardioprotection.
  
  
  METHODS
  This Management of Aspirin-induced Gastro-Intestinal Complications (MAGIC) study was conducted with a prospective nationwide, multicenter, real-world registry of Japanese patients at high-risk of cardiovascular diseases who were taking regular aspirin (75-325 mg) for 1 month or more. All patients underwent endoscopic examination for detection of gastroduodenal ulcer and mucosal erosion. The risk factor profiles including the concurrent drug therapy were compared for those patients with gastroduodenal problems and those without.
  
  
  RESULTS
  Gastroduodenal ulcer and erosion were detected in 6.5, and 29.2% of the 1,454 patients receiving aspirin, respectively. H. pylori infection was associated with an increased risk for ulcer: OR 1.83 (1.18-2.88 p = 0.0082). Risk of erosion was lower with enteric-coated aspirin than with buffered aspirin: odds ratio (OR) 0.47 (0.32-0.70, p = 0.0002). Patients receiving proton pump inhibitors had lower risks for both gastroduodenal ulcer and erosion: OR 0.34 (0.15-0.68, p = 0.0050) and 0.32 (0.22-0.46, p < 0.0001), respectively. However, those receiving histamine 2-receptor antagonists had reduced risks for erosion but not for ulcer: OR 0.49 (0.36-0.68, p < 0.0001).
  
  
  CONCLUSIONS
  Gastroduodenal ulcer and erosion are common in Japanese patients taking low dose aspirin for cardioprotection. Proton pump inhibitors reduce the risk of gastroduodenal mucosal injury.
authors.affiliation: Division of Gastroenterology, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, 272-8516, Japan, nuemura@hospk.ncgm.go.jp.
authors.forename: Naomi
authors.initials: N
authors.lastname: Uemura
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sugano
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Hiraishi
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shimada
authors.forename: Shinya
authors.initials: S
authors.lastname: Goto
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okada
authors.forename: Hideki
authors.initials: H
authors.lastname: Origasa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D016481:Helicobacter Infections / Q000150:complications; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D015995:Prevalence; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000494:pharmacology; D012307:Risk Factors
chemical_list: D006635:Histamine H2 Antagonists; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D001241:Aspirin